Somatostatin receptors and autoimmune-mediated diabetes

Diabetes/Metabolism Research and Reviews

Volumn 21, Issue 1, 2005, Pages 15-30

  Wang, Xaio Ping ^a   Norman, Michael A ^a   Brunicardi, F Charles ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Autoimmune; G protein coupled receptor; Islet hyperplasia; Neuropeptide; Somatostatin

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GROWTH FACTOR; HLA DQ ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEUROTRANSMITTER; NITROGEN DERIVATIVE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; AUTOCRINE EFFECT; AUTOIMMUNE DISEASE; CELL FUNCTION; CELL INFILTRATION; CELL MATURATION; CELL SELECTION; CHROMOSOME 2Q; CHROMOSOME 6P; CLIMATE; COXSACKIE VIRUS; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; ENVIRONMENTAL FACTOR; FOOD INTAKE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATORY CELL; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE CELL; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MENTAL STRESS; MONONUCLEAR CELL; MOUSE; NEUROENDOCRINOLOGY; NONHUMAN; PANCREAS ISLET CELL; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE; THYMOCYTE; VIRUS INFECTION;

AUTOANTIBODIES; AUTOANTIGENS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; MUTATION; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 12744281040     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.531     Document Type: Review

References (200)

1. Norman M, Moldovan S, Seghers V, Wang X, DeMayo FJ, Brunicardi FC. Sulfonylurea receptor knockout causes glucose intolerance in mice which is not alleviated by concomitant somatostatin subtype receptor 5 knockout. Ann Surg 2002; 255: 767-774.
2. Strowski MZ, Kohler M, Chen HY, et al. Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis. Mol Endocrinol 2003; 17: 93-106.
3. Tirone TA, Norman MA, Moldovan S, DeMayo FJ, Wang XP, Brunicardi FC. Pancreatic somatostatin inhibits insulin secretion via SSTR-5 in the isolated perfused mouse pancreas model. Pancreas 2003; 26: 67-73.
4. Atkinson M, Eisenbarth G. Type 1 diabetes: new perspective on disease pathogenesis and treatment. Lancet 2001; 358: 221-229.
5. Bell G, Polonsky K. Diabetes mellitus and genetically programmed defects in beta-cell function. Nature 2001; 414 6865): 788-791.
6. Harris M, Robbins D. Prevalence of adult-onset IDDM in the U.S. population. Diabetes Care 1994; 17: 1337-1340.
7. Chao CC, Sytwu HK, Chen EL, Toma J, McDevitt HO. The role of MHC class II molecules in susceptibility to type I diabetes: identification of peptide epitopes and characterization of the T cell repertoire. Proc Natl Acad Sci U S A 1999; 96: 9299-9304.
8. Davies JL, Kawaguchi Y, Benett ST, et al. A genome wide search for human type 1 diabetes susceptibility genes. Nature 1999; 371: 130-136.
9. Foulis AK, McGill M, Farquharson MA. Insulitis in type 1 (insulin-dependent) diabetes mellitus in man - macrophages, lymphocytes, and interferon-gamma containing cells. J Pathol 1991; 165: 97-103.
10. Kowalewski MA, Urban M, Florys B, Peczynska J. Late potentials. Are they related to cardiovascular complications in children with type 1 diabetes? J Diabetes Complications 2002; 16: 263-270.
11. Guyton GP, Saltzman CL. The diabetic foot: basic mechanisms of disease. Instr Course Lect 2002; 51: 169-181.
12. Karavanaki-Karanassiou K. Autonomic neuropathy in children and adolescents with diabetes mellitus. J Pediatr Endocrinol Metab 2001; 14(Suppl. 5): 1379-1386.
13. Hanazaki K, Nose Y, Brunicardi F. Artificial endocrine pancreas. J Am Coll Surg 2001; 193: 310-322.
14. Hapiro A, Lakey J, Ryan E, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230-238.
15. Boker A, Rothenberg L, Hernandez C, Kenyon N, Ricordi C, Alejandro R. Human islet transplantation: update. World J Surg 2001; 25: 481-486.
16. Hopkins KD. Update on islet-cell transplantation for type 1 diabetes. Lancet 2002; 359(9324): 2172.
17. Sander M, German M. The beta cell transcription factors and development of the pancreas. J Mol Med 1997; 75: 327-340.
18. Sander M, Sussel L, Conners J, et al. Homeobox gene Nkx6.1 lies downstream of Nkx2.2 in the major pathway of beta-cell formation in the pancreas. Development 2000; 127: 5533-5540.
19. Sander M, Neubuser A, Kalamaras J, Ee HC, Martin GR, German MS. Genetic analysis reveals that PAX6 is required for normal transcription of pancreatic hormone genes and islet development. Genes Dev 1997; 24: 36-44.
20. Soria B. In-vitro differentiation of pancreatic beta-cells. Differentiation 2001; 68: 205-219.
21. Leibowitz G, Ferber S, Apelqvist A, et al. IPF1/PDX1 deficiency and beta-cell dysfunction in Psammomys obesus, an animal with type 2 diabetes. Diabetes 2001; 50: 1799-1806.
22. Todd JA. From genome to aetiology in a multifactorial disease, type 1 diabetes. BioEssays 1999; 21: 164-174.
23. Pociot F, McDermott MF. Genetics of type 1 diabetes mellitus. Genes Immun 2002; 3: 235-249.
24. Eisenbarth GS. Type 1 diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986; 314: 1360-1368.
25. Buzzetti R, Quattrocchi C, Nistico L. Dissecting the genetics of type 1 diabetes: relevance for familial clustering and differences in incidence. Diabetes Metab Rev 1998; 14: 111-128.
26. Chentoufi AA, Polychronakos C. Insulin expression levels in the thymus modulate insulin-specific autoreactive T-cell tolerance: the mechanism by which the IDDM2 locus may predispose to diabetes. Diabetes 2002; 51: 1383-1390.
27. Nistico L, Buzzetti R, Pritchard LE, et al. The CTLA-4 gene region on chromosome 2q33 is linked to and associated with type 1 diabetes. Hum Mol Genet 1996; 5: 1075-1080.
28. Larsen Z, Kristiansen O, Mato E, et al. IDDM12 (CTLA4) on 2q33 and IDDM13 on 2q34 in genetic susceptibility to type 1 diabetes (insulin-dependent). Autoimmunity 1999; 31: 35-42.
29. Park Y, Eisenbarth GS. Genetic susceptibility factors of Type 1 diabetes in Asians. Diabetes Metab Res Rev 2001; 958: 309-311.
30. Ben-Shushan E, Marshak S, Shoshkes M, Cerasi E, Melloul D. A pancreatic beta-cell-specific enhancer in the human PDX-1 gene is regulated by hepatocyte nuclear factor 3beta. J Biol Chem 2001; 276: 17 533-17 540.
31. Wood JP, Pani MA, Bieda K, Meyer G, Usadel KH, Badenhoop KA. Recently described polymorphism in the CD28 gene on chromosome 2q33 is not associated with susceptibility to type 1 diabetes. Eur J Immunogenet 2002; 29: 347-349.
32. Ellis TM, Atkinson MA. Early infant diets and insulin-dependent diabetes. Lancet 1996; 347: 1464-1465.
33. Dahlquist GG. Viruses and other perinatal exposures as initiating events for beta-cell destruction. Ann Med 1997; 29 413-417.
34. Knip M, Akerblom HK. Environmental factors in the pathogenesis of type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 1999; 107(Suppl. 3): S93-S100.
35. Foulis AK, Liddle CN, Farquharson MA, Richmond JA, Weir RS. The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: a 25-yr review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 1986; 29: 267-274.
36. Imagawa A, Hanafusa T, Tamura S, et al. Pancreatic biopsy as a procedure for detecting in situ autoimmune phenomena in type 1 diabetes: close correlation between serological markers and histological evidence of cellular autoimmunity. Diabetes 2001; 50: 1269-1273.
37. Verge CF, Stenger D, Bonifacio E, et al. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: combinatorial islet autoantibody workshop. Diabetes 1998; 47: 1857-1866.
38. Bingley PJ, Williams AJ, Gale EA. Optimized autoantibody-based risk assessment in family members. Implications for future intervention trials. Diabetes Care 1999; 22: 1796-1801.
39. Iwagawa A, Hanafusa T, Itoh N, et al. Immunological abnormalities in islets at diagnosis paralleled further deterioration of glycaemic control in patients with recent-onset Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1999; 42: 574-579.
40. Korhonen S, Knip MM, Kulmala P, Savola K, Akerblom HK, Knip M. Autoantibodies to GAD, IA-2 and insulin in ICA-positive first-degree relatives of children with type 1 diabetes: a comparison between parents and siblings. Diabetes Metab Res Rev 2002; 18: 43-48.
41. Hatziagelaki E, Jaeger C, Petzoldt R, et al. The combination of antibodies to GAD-65 and IA-2ic can replace the islet-cell antibody assay to identify subjects at risk of type 1 diabetes mellitus. Horm Metab Res 1999; 31: 564-569.
42. Kimpimaki T, Kulmala P, Savola K, et al. Disease-associated autoantibodies as surrogate markers of type 1 diabetes in young children at increased genetic risk. Childhood Diabetes in Finland Study Group. J Clin Endocrinol Metab 2000; 85: 1126-1132.
43. Panicot L, Mas E, Thivolet C, Lombardo D. Circulating antibodies against an exocrine pancreatic enzyme in type 1 diabetes. Diabetes 1999; 48: 2316-2323.
44. Thivolet C, Abou-Amara S, Martin X, et al. Serological markers of recurrent beta cell destruction in diabetic patients undergoing pancreatic transplantation. Transplantation 2000; 69 99-103.
45. Ziegler AG, Hummel M, Schenker M, Bonifacio E. Appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: The 2-year analysis of the German BABYDIAB study. Diabetes 1999; 48: 460-468.
46. Rewers M, Bugawan TL, Norris JM, et al. Newborn screening for HLA markers associated with IDDM. Diabetes autoimmunity study in the young (DAISY). Diabetologia 1996; 807-812.
47. Nejentsev S, Sjoroos M, Soukka T, et al. Population-based genetic screening for the estimation of type 1 diabetes mellitus risk in Finland: selective genotyping of markers in the HLA-DQB1, HLA-DQA1 and HLA-DRB1 loci. Diab Med 1999; 16: 985-992.
48. Rabinovitch A. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab Rev 1998; 14 129-151.
49. Fujihira K, Nagata M, Moriyama H, et al. Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice. Diabetes 2000; 49: 1998-2006.
50. Karlsen AE, Ronn SG, Lindberg K, et al. Suppressor of cytokine signaling 3 (SOCS-3) protects beta -cells against interleukin-1beta - and interferon-gamma-mediated toxicity. Proc Natl Acad Sci U S A 2001; 98: 12 191-12 196.
51. Atkinson MA, Wilson SB. Fatal attraction: chemokines and type 1 diabetes. J Clin Invest 2002; 110: 1611-1613.
52. Proudfoot AEI. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2002; 2: 106-115.
53. Mellado M, Rodriguesz-Frade JM, Manes S, Martinez C. Chemokine signaling and functional response: the role of receptor dimerization and TK pathway activation. Annu Rev Immunol 2001; 19: 397-421.
54. Luster AD. Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436-445.
55. Chen MC, Proost P, Gysemans C, Mathieu C, Eizirik DL. Monocyte chemoattractant protein-1 is expressed in pancreatic islets from prediabetic NOD mice and in interleukine-1beta-exposed human and rat islet cells. Diabetologia 2001; 44: 325-332.
56. Cameron MJ, Arreaza GA, Grattan M, et al. Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type 1 diabetes. J Immunol 2000; 165: 1102-1110.
57. Kim SH, Cleary MM, Fox HS, Chantry D, Sarvenick N. CCR4-bearing T cells participate in autoimmune diabetes. J Clin Invest 2002; 110.
58. Grattan M, Mi QS, Meagher C, Delovitch TL. Congenic mapping of the diabetogenic locus Idd4 to a 5.2-cM region of chromosome 11 in NOD mice: identification of two potential candidate subloci. Diabetes 2002; 51: 215-223.
59. Szanya V, Ermann J, Taylor C, Holness C, Fathman CG. The subpopulation of CD4(+)CD25(+) splenotypes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR-7. J Immunol 2002; 169: 2461-2465.
60. Green EA, Eynon EE, Flavell RA. Local expression of TNFalpha in neonatal NOD mice promotes diabetes by enhancing presentation of islet antigens. Immunity 1998; 9: 733-743.
61. Dahlen E, Dawe K, Ohlsson L, Hedlund G. Dendritic cells and macrophages are the first and major producers of TNF-alpha in pancreatic islets in the nonobese diabetic mouse. J Immunol 1998; 160: 3585-3593.
62. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-1178.
63. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 26: 314-317.
64. Moriwaki M, Itoh N, Miyagawa J, et al. Fas and Fas ligand expression in inflamed islets in pancreas sections of patients with recent-onset type 1 diabetes mellitus. Diabetologia 1999; 42: 1332-1340.
65. Durant S, Geutskens S, Blokland SCV, et al. Proapoptosis and antiapoptosis-related molecules during postnatal pancreas development in controls and nonobese diabetic mice: relationship with innervation. Lab Invest 2003; 83: 227-239.
66. Petrovsky N, Silva D, Socha L, Slattery R, Charlton B. The role of Fas ligand in beta cell destruction in autoimmune diabetes of NOD mice. Ann N Y Acad Sci 2002; 958: 204-208.
67. Eizirik DL, Mandrup-Poulsen T. A choice of death-the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 2001; 44: 2115-2133.
68. Rossini AA, Mordes JP, Markees TG, Phillips NE, Gordon EJ, Greiner DL. Induction of islet transplantation tolerance suing donor specific transfusion and anti-CD154 monoclonal antibody. Transplant Proc 1999; 31: 629-632.
69. Rossini AA, Mordes JP, Greiner DL, Stoff JS. Islet cell transplantation tolerance. Transplantation 2001; 72: S43-S46.
70. Amrani A, Serra P, Yamanouchi J, et al. CD154-dependent priming of diabetogenic CD4(+) T cells dissociated from activation of antigen-presenting cells. Immunity 2002; 16: 719-732.
71. Carlos TM, Harlan JM. Leukocyte-endothelial adnesion molecules. Blood 1994; 84: 2068-2101.
72. Sharar SR, Winn RK, Harlan JM. The adhesion cascade and anti-adhesion therapy: an overview. Springer Semin Immunopathol 1995; 16: 359-378.
73. Matsumoto K, Sera Y, Ueki Y, Inukai G, Niiro E, Miyake S. Comparison of serum concentrations of soluble adhesion molecules in diabetic macroangiopathy and macroangiopathy. Diabet Med 2002; 19: 822-826.
74. Martin S, van den Engel N, Vinke A, Heidenthal E, Schulte B, Kolb H. Dominant role of intercellular adhesion molecule-1 in the pathogenesis of autoimmune diabetes in non-obese diabetic mice. J Autoimmun 2001; 17: 109-117.
75. Martin S, Vinke A, Heidenthal E, Schulte B, Engel Nvd. Development of low-dose streptozotocin-induced diabetes in ICAM-1-deficient mice. Horm Metab Res 1999; 31: 636-640.
76. Balasa B, Cava AL, Gunst KV, et al. A mechanism for IL-10-mediated diabetes in the nonobese diabetic (NOD) mouse: ICAM-1 deficiency blocks accelerated diabetes. J Immunol 2000; 165: 7330-7337.
77. Camacho SA, Heath WR, Carbone FR, et al. A key role for ICAM-1 in generating effector cells mediating inflammatory responses. Nat Immunol 2001; 2: 523-529.
78. Lenschow DJ, Herold KC, Rhee L, et al. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 1996; 5: 285-293.
79. Wong FS, Visintin I, Wen L, Granata J, Flavell R, Janeway CA. The role of lymphocyte subsets in accelerated diabetes in nonobese diabetic-rat insulin promoter-B7-1 (NOD-RIP-B7-1) mice. J Exp Med 1998; 187: 1985-1993.
80. Dilts SM, Solvason N, Lafferty KJ. The role of CD4 and CD8 T cells in the development of autoimmune diabetes. J Autoimmunity 1999; 13: 285-288.
81. Wong FS Jr. CAJ: The role of CD4 vs. CD8 T cells in IDDM. J Autoimmunity 1999; 13: 290-295.
82. Shizuru JA, Taylor-Edwards C, Banks BS, Gregory AK, Fathman CG. Immunotherapy of the nonobase diabetic mouse: treatment with an antibody to T-helper lymphocytes. Science 1988; 240: 659-662.
83. Wang B, Gonzalez A, Benoist C, Mathis D. The role of CD8+ T cells in the initiation of insulin-dependent diabetes mellitus. Eur J Immunol 1996; 26: 1762-1769.
84. Wong FS, Visintin I, Wen L, Flavell FA, Janeway CA. CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. J Exp Med 1996; 183: 67-76.
85. Balasa B, Krahl T, Patstone G, et al. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol 1997; 159: 4620-4627.
86. Savinov AY, Wong FS, Stonebraker AC, Chervonsky AV. Presentation of antigen by endothelial cells and chemoattraction are required for homing of insulin-specific CD8+ T cells. J Exp Med 2003; 197: 643-656.
87. Herrath MGV, Dockter J, Oldstone M. How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity 1994; 1: 231-242.
88. Wieczorek G, Pospischil A, Perentes E. A comparative immunohistochemical study of pancreatic islets in laboratory animals (rats, dogs, minipigs, nonhuman primates). Exp Toxicol Pathol 1998; 50: 151-172.
89. Taborsky G. Evidence of a paracrine role for pancreatic somatostatin in vivo. Am J Physiol 1983; 245: E598-E603.
90. Itoh M, Mandarino L, Gerich JE. Antisomatostatin gamma globulin augments secretion on both insulin and glucagon in vitro: evidence for a physiologic role for endogenous somatostatin in the regulation of pancreatic A- and B-cell function. Diabetes 1980; 29: 693-696.
91. Samols E, Stagner J. Intraislet regulation. Am J Med 1988; 85: 31-35.
92. Samols E, Stagner J. Islet somatostatin-microvascular, paracrine and pulsatile regulation. Metabolism 1990; 39: 55-60.
93. Samols E, Stagner J, Ewart R, Marks V. The order of islet cellular perfusion is B-A-D in the perfused rat pancreas. J Clin Invest 1988; 82: 350-354.
94. Stagner J, Samols E. The vascular order of islet cellular perfusion in the human pancreas. Diabetes 1992; 41: 93-97.
95. Stagner JI, Samols E, Koerker DJ, Goodner CJ. Perfusion with anti-insulin gamma globulin indicates a B to A to D cellular perfusion sequence in the pancreas of the rhesus monkey, macaca mulatta. Pancreas 1992; 7: 26-29.
96. Stagner JI, Samols E, Bonner-Weir S. B-A-D pancreatic islet cellular perfusion in dogs. Diabetes 1988; 41: 1715-1721.
97. Stagner JI, Samols E, Marks V. Antegrade and retrograde infusion of glucagon antibodies suggests that the A cells are vascularly perfused before D cells within the rat islet. Diabetologia 1989; 32: 203-206.
98. Kleinman R, Ohning G, Wong H, Watt P, Walsh J, Brunicardi F. The regulatory role of intraislet somatostatin on insulin secretion in the isolated perfused human pancreas. Pancreas 1994; 9: 172-178.
99. Kleinman R, Gingerich R, Wong H, et al. Use of the Fab fragment for immunoneutralization of somatostatin in the isolated perfused human pancreas. Am J Surg 1994; 167: 114-119.
100. Kleinman R, Gingerich R, Ohning G, et al. The influence of somatostatin on glucagon and pancreatic polypopeptide secretion in the isolated perfused human pancreas. Int J Pancreatol 1995; 18: 51-57.
101. Kleinman R, Gingerich R, Ohning G, et al. Intraislet regulation of pancreatic polypeptide secretion in the isolated perfused rat pancreas. Pancreas 1997; 15: 384-391.
102. Kleinman R, Fagan S, Ray M, et al. Differential inhibition of insulin and islet amyloid polypeptide secretion by intraislet somatostatin in the isolated perfused human pancreas. Pancreas 1999; 19: 346-352.
103. Brunicardi FC, Kleinman R, Moldovan S, et al. Immunoneutralization of somatostatin, insulin, and glucagon causes alterations in islet cell secretion in the isolated perfused human pancreas. Pancreas 2001; 23: 302-308.
104. Brunicardi FC, Kleinman RM, Ohning G, et al. The inhibitory role of intraislet somatostatin on glucagon secretion in the isolated perfused human pancreas. Transplant Proc 1994; 26: 3451-3452.
105. Brunicardi FC, Wen D, Bradley JC, Elahi D, Miller C, Hanks J. The effect of intraislet somatostatin immunoneutralization on insulin secretion in the isolated perfused rat pancreas. Int J Surg Invest 2000; 1: 381-388.
106. Liu Y, Guth P, Kanko K, Livingston E, Brunicardi F. Dynamic in vivo observation of rat islet microcirculation. Pancreas 1993; 8: 15-21.
107. Moldovan S, Atiya A, Adrian T, et al. Somatostatin inhibits insulin secretion by a type 2 receptor in the isolated perfused human pancreas. J Surg Res 1995; 59: 85-90.
108. 1 cells of the pancreatic islets and to the hypothalamus. Acta Endocrinol 1975; 80: 5-41.
109. Dubois M. Immunoreactive somatostatin is present in discrete cells of the endocrine pancreas. Proc Natl Acad Sci USA 1975; 72 1340-1343.
110. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77-79.
111. 2. Endocrinology 1991; 128: 1754-1762.
112. Montminy M, Goodman R, Horovitch S, Habener J. Primary structure of the gene encoding rat preprosomatostatin. Proc Natl Acad Sci USA 1984; 81: 3337-3340.
113. Goodman R, Aron D, Roos B. Rat pre-prosomatostatin. Structure and processing by microsomal membranes. J Biol Chem 1983; 258 5570-5573.
114. Patel Y, O'Neil W. Peptides derived from cleavage of prosomatostatin at carboxyl- and amino-terminal segments. Characterization of tissue and secreted forms in the rat. J Biol Chem 1988; 263: 745-751.
115. Reisine T, Axelrod J. Prolonged somatostatin treatment desensitizes somatostatin's inhibition of receptor-mediated release of adrenocorticotropin hormone and sensitizes adenylate cyclase. Endocrinology 1983; 113: 811-813.
116. Patel Y General aspects of the biology, function of somatostatin. In Basic, Clinical Aspects of Neuroscience, vol 4, Weil C, Muller E, Thorner M (eds). Springer-Verlag: Berlin, 1992; 1-16.
117. Larsson L. Distribution and morphology of somatostatin cells. Adv Exp Biol Med 1985; 188.
118. Baetens D, Malaisse-Lagae F, Perrelet A, Orci L. Endocrine pancreas: three-dimensional reconstruction shows two types of islets of Langerhans. Science 1979; 206: 1323-1325.
119. Yasuda K, Rens-Domiano S, Breder C, et al. Cloning of a novel somatostatin receptor, SSTR3, coupled to adenylate cyclase. J Biol Chem 1992; 267: 20 422-20 428.
120. Bruno J, Xu Y, Song J, Berelowitz M. Molecular cloning and functional expression of a brain-specific somatostatin receptor. Proc Natl Acad Sci USA 1992; 89: 11151-11155.
121. Moldovan S, DeMayo F, Brunicardi F. Cloning of the mouse SSTR5 gene. J Surg Res 1998; 76: 57-60.
122. Raynor K, Murphy WA, Coy DH, et al. Clone somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. Mol Pharmacol 1993; 43: 838-844.
123. Raynor K, O'Carroll AM, Kong HY, et al. Characterization of cloned somatostatin receptors SSTR4 and SSTR5. Mol Pharmacol 1993; 44: 385-392.
124. Rossowski W, Coy D. Potent inhibitory effects of a type four receptor-selective somatostatin analog on rat insulin release. Biochem Biophys Res Commun 1993; 197: 366-371.
125. Capecchi M. Targeted gene replacement. Sci Am 1994; 270: 52-59.
126. Thomas KR, Capecchi MR. Introduction of homologous DNA sequences into mammalian cells induces mutations in the cognate gene. Nature 1986; 324: 34-38.
127. Amherdt M, Patel Y, Orci L. Selective binding of somatostatin-14 and somatostatin-28 to islet cells revealed by quantitative electron microscopic autoradiography. J Clin Invest 1987; 80: 1455-1458.
128. Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Sein S. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci U S A 1992; 89: 251-255.
129. Patel Y, Greenwood M, Kent G, Panetta R, Srikant C. Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. Biochem Biophys Res Commun 1993; 192: 288-294.
130. Vanetti M, Kouba M, Wang X, Vogt G, Hollt V. Cloning and expression of a novel mouse somatostatin receptor (SSTR2B). FEBS Lett 1992; 311: 290-294.
131. Bruns C, Raulf F, Hoyer D, Schloos J, Lubbert H, Weckbecker G. Binding properties of somatostatin receptor subtypes. Metabolism 1996; 45: 17-20.
132. Reisine T, Bell G. Molecular biology of somatostatin receptors. Endocrinol Rev 1995; 16: 427-442.
133. Hoyer D, Bell G, Berelowitz M, et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 1995; 16: 86-88.
134. Patel Y, Srikant C. Somatostatin receptors. Trends Endocrinol Metab 1997; 8: 398-405.
135. Taylor J, Coy D. The receptor pharmacology of somatostatin agonists and antagonists: implications for clinical utility. J Endocrinol Invest 1997; 20: 8-10.
136. Nehring R, Meyerhof W, Richter D. Aspartic acid residue 124 in the third transmembrane domain of the somatostatin receptor subtype 3 is essential for somatostatin-14 binding. DNA Cell Biol 1995; 14 939-944.
137. Kaupmann K, Bruns C, Raulf F, Weber H, Mattes H, Lubbert H. Two amino acids, located in transmembrane domains VI and VII, determine the selectivity of the peptide agonist SMS201-995 for the SSTR2 somatostatin receptor. EMBO J 1995; 14: 727-735.
138. Raynor K, Wang H, Dichter M, Reisine T. Subtypes of brain somatostatin receptors couple to multiple cellular effector systems. Mol Pharmacol 1991; 40: 248-253.
139. Emami S, Regnauld K, Ferrand N, et al. Stimulatory transducing systems in pancreatic islet cells. Ann N Y Acad Sci 1998; 865: 118-131.
140. Koch B, Blalock J, Schonbrunn A. Characterization of the cyclic AMP-independent actions of somatostatin in GH cells. I. An increase in potassium conductance is responsible for both the hyperpolarization and the decrease in intracellular free calcium produced by somatostatin. J Biol Chem 1988; 263: 216-225.
141. Bosch F, Pujol A, Valera A. Transgenic mice in the analysis of metabolic regulation. Ann Rev Nutr 1998; 18: 207-232.
142. White R, Schonbrunn A, Armstrong D. Somatostatin stimulates Ca2+-activated K+channels through protein dephosphorylation. Nature 1991; 351: 570-573.
143. Tietz PS, Alpini G, Pham LD, Larusso NF. Somatostatin inhibits secretin-induced ductal hypercholeresis and exocytosis by cholangiocytes. Am J Physiol Endocrinol Metab 1995; 269: G110-G118.
144. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20: 157-198.
145. Kreienkamp HJ, Houck HH, Richter D. Coupling of rat somatostatin receptor subtypes to a G-protein gated inwardly rectifying potassium channel (GIRK1). FEBS Lett 1997; 419: 92-94.
146. Sharma K, Patel YC, Srikant CB. C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest. Mol Endocrinol 1999; 13: 82-90.
147. Strader C, Fong T, Graziano M, Tota M. The family of G protein coupled receptors. FASEB J 1995; 9: 745-754.
148. Hukovic N, Panetta R, Kumar U, Patel Y. Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. Endocrinology 1996; 137: 4046-4049.
149. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 2000; 275: 7862-7869.
150. Pfeiffer M, Koch T, Schroder H, et al. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J Biol Chem 2001; 276: 14027-14036.
151. Pfeiffer M, Koch T, Schroder H, Laugsch M, Hollt V, Schulz S. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization and desensitization. J Biol Chem 2002; 277: 19 762-19 772.
152. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000; 288: 154-157.
153. Patel Y, Greenwood M, Panetta R, Demchyshyn L, Niznik H, Srikant C. The somatostatin receptor family: a mini review. Life Sci 1995; 57: 1249-1265.
154. Hasegawa G, Sawada M, Nakamura N, Nakano K, Kondo M. The effects of overeating on insulin secretion in normal mice. Diabetes Res 1991; 17: 139-145.
155. Kumar U, Laird D, Srikant CB, Escher E, Patel YC. Expression of the five somatostatin receptor (SSTR1-5) subtypes in rat pituitary somatotrophes: quantitative analysis by double-label immunofluorescence confocal microscopy. Endocrinology 1997; 138: 4473-4476.
156. Kumar U, Ong W-Y, Patel S, Patel Y. Cellular expression of the five somatostatin receptor subtypes (SSTR1-5) in rat hypothalamus: a comparative immunohistochemical analysis. Program Annual Meeting US Endocrine Society, San Diego, 1999.
157. Kumar U, Sasi R, Suresh S, et al. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 1999; 48: 77-85.
158. Raulf F, Perez J, Hoyer D, Bruns C. Differential expression of five somatostatin receptor subtypes, SSTR1-5, in the CNS and peripheral tissue. Digestion 1994; 55: 46-53.
159. Portela-Gomes GM, Stridsberg M, Grimelius L, Oberg K, Janson ET. Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. Appl Immunohistochem Mol Morphol 2000; 8: 126-132.
160. Chowen-Breed J, Steiner R, Clifton D. Sexual dimorphism and testosterone dependent regulation of somatostatin gene expression in the periventricular nucleus of the rat brain. Endocrinology 1989; 125: 357-362.
161. Rossowski W, Coy D. Specific inhibition of rat pancreatic insulin or glucagon release by receptor-selective somatostatin analogs. Biochem Biophys Res Commun 1994; 205: 341-346.
162. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. J Clin Invest 1997; 100: 2386-2392.
163. Zheng H, Bailey A, Jiang MH, et al. Somatostatin receptor subtype 2 knockout mice are refractory to growth hormone-negative feedback on arcuate neurons. Mol Endocrinol 1997; 11: 1709-1717.
164. Martinez V, Curi A, Torkian B, et al. High basal gastric acid secretion in somatostatin receptor subtype 2 knockout mice. Gastroenterology 1998; 114: 1125-1132.
165. Kreienkamp H, Akgun E, Baumeister H, Meyerhof W, Richter D. Somatostatin receptor subtype 1 modulates basal inhibition of growth hormone release in somatotrophs. FEBS Lett1999; 462: 464-466.
166. Ishihara S, Hassan S, Kinoshita Y, et al. Growth inhibitory effects of somatostatin on human leukemia cell lines mediated by somatostatin receptor subtype 1. Peptides 1999; 20: 313-318.
167. Strowski M, Parmar R, Blake A, Schaeffer J. Somatostatin inhibits insulin and glucagon secretion via 2 receptor subtypes: an in vitro study of pancreatic islets for somatostatin receptor 2 knockout mice. Endocrinology 2000; 141: 111-117.
168. Fegan SP, Azizzadeh A, Moldovan S, et al. Insulin secretion is inhibited by subtype five somatostatin receptor in the mouse. Surgery 1998; 124: 254-259.
169. Bhathena SJ, Louies J, Schechter GP, Redman RS, Wahl L, Recant L. Identification of human mononuclear leukocytes bearing receptors for somatostatin and glucagon. Diabetes 1981; 30: 127-131.
170. Lichtenauer-Kaligis EGR, Hagen PMv, Lamberts SWJ, Hofland LJ. Somatostatin receptor subtypes in human immune cells. Eur J Endocrinol 2000; 143: S21-S25.
171. Weinstock JV, Elliott D. The somatostatin immunoregulatory circuit present at sites of chronic inflammation. Eur J Endocrinol 2000; 143: S15-S19.
172. Oomen SPMA, Hennik PBv, Antonissen C, et al. Somatostatin is a selective chemoattractant for primitive (CD34+) hematopoietic progenitor cells. Exp Hematol 2002; 30: 116-125.
173. Patel YC, Liu J, Galanopoulou A, Parachristou DN Production, action, and degradation of somatostatin. In Handbook of Physiology. Section 7: The Endocrine System; Jefferson LS, Cherrington AD, Goodman HM (eds). Oxford University Press: Oxford, 2001; 267-302.
174. Ferone D, Hagen MPv, Kwekkeboom DJ, et al. Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro. J Clin Endocrinol Metab 2000; 85: 1719-1726.
175. Feron D, Hofland LJ, Colao A, Lamberts SW, Hagen PMv. Neuroendocrine aspects of immunolymphoproliferative diseases. Ann Oncol 2001; 12: S125-S130.
176. Levite M. Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype. Proc Natl Acad Sci U S A 1998; 95: 12 544-12 549.
177. Krantic S. Peptides as regulators of the immune system: emphasis on somatostatin. Peptides 2000; 21: 1941-1964.
178. Oomen SPMA, Hofland JJ, Hagen PMv, Lamberts SWJ, Touw IP. Somatostatin receptors in the haematopoietic system. Eur J Endocrinol 2000; 143: S9-S14.
179. Pages P, Benali N, Saint-Laurent N, et al. sst2 somatostatin receptor mediates cell cycle arrest and induction of p27Kip1. J Biol Chem 1999; 274: 15 186-15 193.
180. Kaltschmidt B, Kaltschmidt C, Hehner SP, Droge W, Schmitz ML. Repression of NF-kB impairs HeLa cell proliferation by functional interference with cell cycle checkpoint regulators. Oncogene 1999; 18: 3213-3225.
181. Bito H, Mori M, Sakanaka C, et al. Functional coupling of SSTR4, a major hippocampal somatostatin receptor, to adenylate cyclase inhibition, arachidonate release and activation of the mitogen-activated protein kinase cascade. J Biol Chem 1994; 269.
182. Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 1996; 10: 1688-1696.
183. Ferone D, Hagen PMv, Pivonello R, Colao A, Lamberts SWJ, Hofland LJ. Physiological and pathophysiological role of somatostatin receptors in the human thymus. Eur J Endocrinol 2000; 143: S27-S34.
184. Kendall MD (ed). Age and Seasonal Changes in the Thymus Academic: London, 1981.
185. Nakahama M, Mohri N, Mori S, Shindo G, Yokoi Y, Machinami R. Immunohistochemical and histometrical studies on the human thymus with special emphasis on age-related changes in medullary epithelial and dendritic cells. Virchows Arch 1990; 58: 245-251.
186. Anderson G, Moore NC, Owen JJT, Jenkinson EJ. Cellular interactions in thymocyte development. Ann Rev Immunol 1996; 14 73-99.
187. Solomou K, Ritter MA, Palmer DB. Somatostatin is expressed in the murine thymus and enhances thymocyte development. Eur J Immunol 2002; 32: 1550-1559.
188. Reubi JC, Waser B, Jorisberger U, et al. In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue. Blood 1993; 82: 2143-2151.
189. Throsby M, Homo-Delarche F, Chevenne D, Goya R, Dardenne M, Pleau J-M. Pancreatic hormone expression in the murine thymus: localization in dendritic cells and macrophages. Endocrinology 1998; 139: 2399-2406.
190. Ferone D, Hagen PV, Koetsveld PV, et al. In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells. Endocrinology 1999; 140: 373-380.
191. Ferone D, Pivonello R, Hagen PMv, et al. Age-related decrease of somatostatin receptor number in the normal human thymus. Am J Physiol Endocrinol Metab 2000; 279: E791-E798.
192. Ferone D, Pivonello R, Hagen PMv, et al. Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. Am J Physiol Endocrinol Metab 2002; 283: E1056-E1066.
193. Ghamrawy CE, Rabourdin-Combe C, Krantic S. SST5 somatostatin receptor mRNA induction by mitogenic activation of human T lymphocytes. Peptides 1999; 20: 305-311.
194. Chiba T, Taminato T, Kadowaki S, et al. Reversal of increased gastric somatostatin in streptozotocin-diabetic rats by whole pancreas transplantation. Diabetes 1981; 30: 724-727.
195. Chao TC, Cheng HP, Walter R. Somatostatin and macrophage function: modulation of hydrogen peroxide, nitric oxide and TNF release. Regul Pept 1995; 58: 1-10.
196. Ferone D, Hagen PMv, Colao A, Annunziato L, Lamberts SWJ, Hofland LJ. Somatostatin receptors in the thymus. Ann Med 1999; 31: 28-33.
197. Scicchitano, R, Dazin P, Bienenstock J, Payan DG, Stanisz AM. Distribution of somatostatin receptors on murine spleen and Peyer's patch T and B lymphocytes. Brain Behav Immun 1987; 1: 173-184.
198. Gagnerault MC, Luan JJ, Lotton C, Lepault F. Pancreatic lymph nodes are required for priming of b cell reactive T cells in NOD mice. J Exp Med 2002; 196: 369-377.
199. Reubi JC, Horsberger U, Saser B, Gebbers JO, Laissue J. Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue. Gastroenterology 1992; 103: 1207-1214.
200. Green EA, Choi Y, Falvell RA. Pancreatic lymph node-derived CD4+CD25+ treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity 2002; 16: 183-191.